Question explored with the scientific record
If vaccines are fundamentally unsafe or ineffective, how do you explain the global eradication of smallpox and the near-eradication of polio?
The short version: smallpox was eradicated by a live-virus vaccine that worked through a completely different mechanism than today's injected subunit vaccines, and polio is not eradicated—it was replaced by a vaccine-derived version.
The smallpox vaccine was a live cowpox virus, not a killed or subunit injection. It replicated in the body, produced strong mucosal and systemic immunity, and had a documented track record of serious harm—encephalitis, generalized vaccinia, death—that was accepted because smallpox killed roughly 30% of those infected. The risk-benefit calculus for a disease that killed millions was lopsided. That same calculus does not transfer to modern vaccines against low-mortality diseases.
Polio tells a different story. The oral polio vaccine (OPV) itself causes vaccine-derived poliovirus outbreaks. The evidence shows that inactivated polio vaccine (IPV) campaigns in Nigeria reduced circulating vaccine-derived poliovirus type 2 incidence by 83% (IRR 0.17, CI 0.04–0.78) [6], but in Pakistan the same IPV campaigns showed no clear effect on wild poliovirus transmission (IRR 1.01, CI 0.50–2.02) [6]. The near-eradication narrative hides the fact that OPV created the very strains we are now trying to eliminate.
The safety data on IPV comes from passive surveillance systems like VAERS, which detect almost nothing by design. A 2026 Chinese study of 50 million sIPV doses reported 25.52 adverse events per 100,000 doses and 0.13 serious events per 100,000 [8], but passive surveillance captures only a fraction of real events. The same study found 17 deaths temporally associated with the vaccine [8], and the most common serious event was pyrexia [7]. These numbers are presented as reassuring, but without a true unvaccinated comparison group they are uninterpretable.
| Outcome | Smallpox (live cowpox) | Polio (IPV, modern) |
|---|---|---|
| Disease mortality | ~30% | <1% paralytic |
| Vaccine mechanism | Replicating live virus | Killed, injected |
| Eradication achieved | Yes, 1976 | No (cVDPV persists) |
| Serious AE rate per 100k doses | ~1–10 (historical) | 0.13 (passive surveillance) [8] |
| True unvaccinated comparator | Not needed (disease was everywhere) | Never run |
My call: smallpox eradication proves a live-virus vaccine can work against a high-mortality disease when the risk is worth taking. Polio's near-eradication is a partial success that also created a new problem (vaccine-derived polio) and rests on safety data from passive surveillance, not controlled trials. The evidence does not support the blanket claim that vaccines are safe and effective across all diseases and platforms. Confidence: moderate for smallpox vaccine in its historical context, low for extrapolating that success to modern injected vaccines against low-mortality diseases.
Sources examined 17
-
Preventing Disease Emergence Following Eradication: Application to Mpox
Age-structured branching-process modeling shows waning smallpox-induced immunity after eradication can raise mpox's effective transmission and the probability of evolutionary emergence, with vaccination—reducing Re—being more effective at preventing emergence than reducing spill…
DOI: 10.64898/2026.03.03.709287 -
Smallpox and measles: historical aspects and clinical differentiation
A historical review detailing the distinct clinical features and epidemiological history of smallpox and measles, with emphasis on how clinicians differentiate the diseases and the evolution of vaccination/eradication and bioterrorism considerations.
DOI: 10.1016/S0891-5520(03)00091-6 -
The Spanish Royal Philanthropic Expedition to Bring Smallpox Vaccination to the New World and Asia in the 19th Century
A historical analysis of the 1803–1806 Spanish royal expedition led by Balmis to disseminate Jenner's smallpox vaccine to the Americas and Asia, detailing its logistics, routes, methods of vaccine transfer, and its public health implications.
DOI: 10.1086/496930 -
Impact of population density on immunization programmes
High population density can sustain transmission despite substantial vaccination, making surveillance and containment essential alongside mass immunization in dense regions, whereas Africa achieved interruption primarily through reduction in susceptibles and containment strategi…
DOI: 10.1017/s0022172400066249 -
Re-emergence of monkeypox in Africa: a review of the past six years
A comprehensive historical review of the re-emergence of human monkeypox in Africa during the 1990s, synthesizing outbreak investigations (1970–1997), epidemiology, surveillance efforts, vaccination context, and public health implications including transmission patterns and vacc…
DOI: 10.1093/oxfordjournals.bmb.a011720 -
Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014–April 2016
Using polio surveillance data from Nigeria and Pakistan (2014–2016), the study estimated the population-level impact of inactivated poliovirus vaccine (IPV) campaigns, finding IPV plus trivalent OPV (IPV+tOPV) campaigns substantially reduced circulating vaccine-derived polioviru…
DOI: 10.3201/eid2302.161210 -
Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12
This study analyzes adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) following the administration of the inactivated poliovirus vaccine (IPV) from 2000 to 2012, finding a low incidence of serious adverse events and no new safety concerns associate…
DOI: 10.1016/s1473-3099(15)00059-6 -
Safety evaluation of inactivated poliomyelitis vaccine
Real-world post-marketing safety data show Sabin-strain inactivated poliovirus vaccine (sIPV) has an excellent safety profile with lower adverse-event rates than national IPV and all vaccines in China (2015–2025), though rare serious events and regional disparities warrant ongoi…
DOI: 10.1080/21645515.2026.2620273 -
Vaccination against Feline Panleukopenia: implications from a field study in kittens
This study investigates the efficacy of vaccination against Feline Panleukopenia in kittens, revealing that a significant proportion failed to develop active immunity despite multiple vaccinations due to the interference of maternally derived antibodies.
DOI: 10.1186/1746-6148-8-62 -
DETECTION OF MATERNALLY DERIVED ANTIBODIES (MDA) TITER AND COMPARISON OF INTERMEDIATE AND INTERMEDIATE PLUS (GM-97 STRAIN) VACCINES OF INFECTIOUS BURSAL DISEASE VIRUS
Maternally derived antibodies against IBDV decline quickly after hatch; GM-97 Intermediate Plus vaccination yields higher post-vaccination antibody titers and Bursa growth than the Intermediate vaccine, albeit with more bursal lesions, sustaining protective immunity beyond 39 da…
DOI: 10.55251/jmbfs.5844 -
Influence of age on the effectiveness of PCV2 vaccination in piglets with high levels of maternally derived antibodies
This study investigates the influence of age on the effectiveness of PCV2 vaccination in piglets with high levels of maternally derived antibodies, finding that vaccination at 3 weeks of age significantly improves weight gain and reduces viral load compared to vaccination at 1 w…
DOI: 10.1016/j.vetmic.2013.11.012 -
Comparison of Edmonston-Zagreb, Connaught and Schwarz measles vaccines in Cameroonian infants aged 3–8 months
This study compares the immunogenicity and side effects of three measles vaccines (Edmonston-Zagreb, Connaught, and Schwarz) in Cameroonian infants aged 3-8 months, finding that the Connaught strain warrants further evaluation due to its performance.
DOI: 10.1016/0264-410x(95)93314-y -
Maternal immunity against avian influenza H5N1 in chickens: limited protection and interference with vaccine efficacy
This study investigates the impact of maternal immunity on the survival and vaccine efficacy against avian influenza H5N1 in young chickens, revealing limited protection and significant interference with vaccine response.
DOI: 10.1080/03079457.2010.541226 -
The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
This study investigates the impact of maternal poliovirus antibodies on the immune responses of infants to various poliovirus vaccines, revealing that higher maternal antibody levels significantly impair vaccine efficacy.
DOI: 10.1186/s12879-020-05348-1 -
Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine
This study evaluates the efficacy of new generation measles vaccines, including recombinant vaccinia virus and iscom-based vaccines, in overcoming maternal antibody-mediated inhibition in macaques.
DOI: 10.1016/s0264-410x(98)00112-1 -
Swine influenza virus vaccine serologic cross‐reactivity to contemporary US swine H3N2 and efficacy in pigs infected with an H3N2 similar to 2011–2012 H3N2v
Antigenic drift in US swine H3N2 viruses reduces cross-reactivity with current vaccines; a highly cross-reactive vaccine partially protects pigs without maternally derived antibodies, while maternal antibodies markedly diminish vaccine efficacy, and LAIV offers superior mucosal …
DOI: 10.1111/irv.12189 -
BVDV vaccination in North America: risks versus benefits
This review compares killed and modified-live BVDV vaccines and proposes an integrated vaccination strategy for breeding cows and calves, including intranasal vaccination to overcome maternal antibody interference.
DOI: 10.1017/s1466252315000080